Search company, investor...

Predict your next investment

Venture Capital
epidarex.com

Investments

49

Portfolio Exits

5

Funds

3

Partners & Customers

1

About Epidarex Capital

Epidarex Capital, formerly Rock Spring Ventures, funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today's healthcare market. Epidarex invests in early-stage high growth life science and health technology companies in under-ventures markets within the UK and US.

Headquarters Location

7910 Woodmont Avenue Suite 1210

Bethesda, Maryland, 20814,

United States

301-298-5455

Want to inform investors similar to Epidarex Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Epidarex Capital News

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease

Sep 13, 2023

Roche Venture Fund joins existing major investors Epidarex Capital, Sofinnova Partners and BioGeneration Ventures September 13, 2023: Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease, today announces an extension of its Series A financing round, with the total amount raised by the Company since inception now £35 million. New investor Roche Venture Fund has joined existing investors Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, the University of Strathclyde, Scottish Enterprise and the European Investment Fund. The Company will use the proceeds to progress its lead discovery programme through IND-enabling studies and to extend its patent estate. “With this financing and an outstanding syndicate of investors, we will continue to advance our novel drug candidates towards the clinic with the goal of developing a disease-modifying therapy for patients with ADPKD,” said Neil Wilkie, CEO of Mironid. “The financing validates our drug development strategy enabling us to transition from discovery to development of powerful new medicines for a chronically debilitating disease with presently limited treatment options.” David Evans from Roche Venture Fund said: “We were very pleased to participate in this funding round. We were impressed by the foundational science and the team at Mironid and believe the Company’s small molecules have meaningful potential to improve the lives of patients with ADPKD. We are looking forward to working with the management team as the lead programme moves through IND-enabling studies and towards clinical development.” ADPKD is one of the more prevalent rare diseases and the most common hereditary kidney disorder. It affects over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60. The disease is caused predominantly by mutations in the PKD1 or PKD2 gene and is characterized by uncontrolled growth of fluid-filled cysts in the kidney. Mironid’s first-in-class LoAc® small molecules represent the only drug class directly targeting the cellular signal, cyclic AMP (cAMP), which is active in all stages of the disease process from initiation through to end-stage, stimulating both cell proliferation and fluid secretion. Robust in vitro and disease model data show significant efficacy across all disease endpoints, including a reduction in cyst number and kidney volume. The ability of cAMP modulators to prevent new cyst formation and arrest the growth of existing cysts is indicative of the potential to deliver clinical benefit to all ADPKD patients. Moreover, this drug class could offer an improved side-effect profile, most importantly in reduced polyuria, which is a significant cause of poor compliance with current therapies. -ENDS- About Mironid Mironid is a biopharmaceutical company developing small molecule therapeutics for the treatment of life-threatening hereditary kidney disease. Its lead programme is for Autosomal Dominant Polycystic Kidney Disease (ADPKD), which is characterized by uncontrolled growth of fluid-filled cysts and is the most common hereditary kidney disorder, but has limited treatment options. Mironid’s first-in-class small molecule LoAc® drug candidates directly target the abnormally high kidney cAMP levels that drive cyst formation. The Company is led by an industry-experienced management team and supported by a strong advisory network and blue-chip investors including Roche Venture Fund, Epidarex Capital, Sofinnova Partners and BioGeneration Ventures. The University of Strathclyde, Scottish Investment Bank and the European Investment Fund (EIF) are also investors in Mironid. About Roche Venture Fund The Roche Venture Fund is the corporate venture fund of Roche and invests in innovative life science companies. Over the past 20 years, the Roche Venture Fund has invested in over 60 companies globally and currently has a portfolio of around 30 companies located in 10 countries. As part of a multinational healthcare company, the Roche Venture Fund has access to considerable expertise both internally and externally and co-invests with leading venture funds, including other corporate venture funds, on a regular basis. About Epidarex Capital Epidarex Capital is a transatlantic venture capital firm with a track record of building exceptional life science companies in emerging hubs in the US and UK. Epidarex’ experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in the global healthcare market. www.epidarex.com About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com About BioGeneration Ventures BioGeneration Ventures (BGV) is a venture capital company, with a focus on early-stage European biotech companies. With a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies, BGV manages over EUR 250 million of funds and invests in areas where true scientific innovations, unmet medical needs, and the potential to demonstrate a significant proof of concept all converge. BGV strives to work with founding teams to progress science and build successful companies and uses its experience to guide progress into clinical trials, leading to successful drug development and value realization for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. BGV operates a joint-venture with Forbion as the early stage strategy of the Forbion platform, focusing on company creation and seed/Series A investments. The Company is based in Naarden, The Netherlands. For more information, please visit: http://www.biogenerationventures.com . About Scottish Enterprise Scottish Enterprise (SE) is Scotland’s national economic development agency and a non-departmental public body of the Scottish Government. It supports businesses to innovate and scale to transform the Scottish economy by focusing on new market opportunities through targeted investment, innovation and internationalisation. Follow us on Twitter and LinkedIn .

Epidarex Capital Investments

49 Investments

Epidarex Capital has made 49 investments. Their latest investment was in Mironid as part of their Series A - II on September 9, 2023.

CBI Logo

Epidarex Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/13/2023

Series A - II

Mironid

No

1

1/17/2023

Seed VC - II

Slate Bio

$1.35M

No

1

11/18/2022

Series A

Nyra Medical

$20M

Yes

13

5/31/2022

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

4/7/2022

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/13/2023

1/17/2023

11/18/2022

5/31/2022

4/7/2022

Round

Series A - II

Seed VC - II

Series A

Seed VC - II

Seed VC

Company

Mironid

Slate Bio

Nyra Medical

Subscribe to see more

Subscribe to see more

Amount

$1.35M

$20M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

13

10

10

Epidarex Capital Portfolio Exits

5 Portfolio Exits

Epidarex Capital has 5 portfolio exits. Their latest portfolio exit was Sirakoss on November 03, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/3/2020

Acquired

$99M

2

10/7/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/6/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

11/9/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

8/8/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/3/2020

10/7/2020

12/6/2017

11/9/2017

8/8/2017

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Epidarex Capital Fund History

3 Fund Histories

Epidarex Capital has 3 funds, including Epidarex Capital III UK.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/22/2020

Epidarex Capital III UK

$127M

1

5/30/2014

Epidarex Capital UK Life Science & Health Tech Fund

Subscribe to see more

Subscribe to see more

$99M

10

Epidarex Capital III US

Subscribe to see more

Subscribe to see more

10

Closing Date

6/22/2020

5/30/2014

Fund

Epidarex Capital III UK

Epidarex Capital UK Life Science & Health Tech Fund

Epidarex Capital III US

Fund Type

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Amount

$127M

$99M

Sources

1

10

10

Epidarex Capital Partners & Customers

1 Partners and customers

Epidarex Capital has 1 strategic partners and customers. Epidarex Capital recently partnered with Selvita on October 10, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

10/31/2016

Partner

Poland

1

Date

10/31/2016

Type

Partner

Business Partner

Country

Poland

News Snippet

Sources

1

Epidarex Capital Team

4 Team Members

Epidarex Capital has 4 team members, including current Managing Partner, A. Sinclair Dunlop.

Name

Work History

Title

Status

A. Sinclair Dunlop

Masa Inc., and New Vantage Group

Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

A. Sinclair Dunlop

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Masa Inc., and New Vantage Group

Title

Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.